Advanced Diagnosis and Profiling in Neurotrauma using Novel Astrocyte Injury-Defined, AID, Biomarker Tests.

T. Van Meter, N. Mirshahi, V. Parrilli, and I-B. Wanner
BRAINBox Solutions, Inc., United States

Keywords: mTBI, concussion, diagnosis, risk, biomarker

Evaluation of mild traumatic brain injury (TBI) and concussion is difficult due to limited sensitivity of currently used neurotrauma biomarkers. A novel panel of proteins was recently identified as being rapidly and substantially released from traumatized astrocytes (Astrocyte Injury-Defined, "AID" biomarkers, Halford et al., JCBFM 2017). AID markers were significantly elevated in TBI patients and were robustly present in blood early after mild TBI. The advancement of these biomarkers into widespread clinical use depends on well-characterized and isoform-specific antibody pairs to sensitively detect these blood-borne brain-specific proteins. Three AID biomarkers, Aldolase C (ALDOC), Brain Lipid Binding Protein (BLBP), and a novel small breakdown product of Glial Fibrillary Acidic Protein (smBDP-GFAP), have been the target of innovation funding to our laboratories to create and test clinical grade antibody pairs for making robust assays to these analytes. We have conducted accuracy studies on these analytes and compared them with other neurotrauma biomarkers and provide performance examples. The utility of AID biomarkers for TBI diagnosis and risk assessment for symptoms and outcomes could dramatically improve warfighter and general TBI patient care. Further validation of such novel detection assays and technologies for rapid field-based application are warranted.